In 2018, the National Cancer Institute estimates there will be 1,735,000 new cases of cancer diagnosed in the U.S.
During the past 12 months, health care ads have reached 75% of U.S. cancer survivors on television, 54% at doctor’s offices and 40% via magazines.
When asked what sources of information they value the most, it’s no surprise that all survivors look primarily to their medical support team (doctors, nurses, pharmacists), medication packaging/labels and family/friends.
Pharma companies don’t really care about patients despite all their hubris.
PhRMA has already spent $21 million on lobbying this year — a sum that puts it on course to smash its previous annual lobbying records.
Pharmaceutical companies have been top performers in the healthcare sector in an era of aging populations, rising health care costs, and the ongoing development of new and extremely profitable medicines.
Research shows that 78 percent of patents approved by the U.S. Food and Drug Administration correspond to medications already on the market.
Large pharma companies spend more on share buybacks to boost share prices (and stock options — the main way that executives get paid) than on research and development.
Employee’s are once again getting hit with more of the costs of their coverage in the form of higher premiums and higher deductibles.
Health care premiums continue to take up more of employees’ paychecks.
Just over a quarter of all covered employees are enrolled in policies with a deductible of at least $2,000, up from 22 percent last year and 15 percent five years ago.
Worldwide obesity has nearly tripled since 1975, according to the World Health Organization. In 2016, more than 600 million adults were obese — or about 13 percent of the world’s population leading to a jump in cancer cases and other costly health conditions. Continue reading →